Advertisement

Behavioral Responses to Catecholamine Depletion in Unmedicated, Remitted Subjects with Bulimia Nervosa and Healthy Subjects

      Abstract

      Background

      Bulimia nervosa (BN) has been associated with dysregulation of the central catecholaminergic system. An instructive way to investigate the relationship between catecholaminergic function and psychiatric disorder has involved behavioral responses to experimental catecholamine depletion (CD). The purpose of this study was to examine a possible catecholaminergic dysfunction in the pathogenesis of bulimia nervosa.

      Methods

      CD was achieved by oral administration of alpha-methyl-para-tyrosine (AMPT) in 18 remitted female subjects with BN (rBN) and 31 healthy female control subjects. The study design consisted of a randomized, double blind, placebo-controlled crossover, single-site experimental trial. The main outcome measures were bulimic symptoms assessed by the Eating Disorder Examination—Questionnaire. Measures were assessed before and 26, 30, 54, 78, 102 hours after the first AMPT or placebo administration.

      Results

      In the experimental environment (controlled environment with a low level of food cues) rBN subjects had a greater increase in eating disorder symptoms during CD compared with healthy control subjects (condition × diagnosis interaction, p < .05). In the experimental environment, rBN subjects experienced fewer bulimic symptoms than in the natural environment (uncontrolled environment concerning food cues) 36 hours after the first AMPT intake (environment × diagnosis interaction, p < .05). Serum prolactin levels increased significantly, and to a comparable degree across groups, after AMPT administration.

      Conclusions

      This study suggests that rBN is associated with vulnerability for developing eating disorder symptoms in response to reduced catecholamine neurotransmission after CD. The findings support the notion of catecholaminergic dysfunction as a possible trait abnormality in BN.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Buckholtz N.S.
        • George D.T.
        • Davies A.O.
        • Jimerson D.C.
        • Potter W.Z.
        Lymphocyte beta-adrenergic receptor modification in bulimia.
        Arch Gen Psychiatry. 1988; 45: 479-482
        • George D.T.
        • Kaye W.H.
        • Goldstein D.S.
        • Brewerton T.D.
        • Jimerson D.C.
        Altered norepinephrine regulation in bulimia: Effects of pharmacological challenge with isoproterenol.
        Psychiatry Res. 1990; 33: 1-10
        • Fulton S.
        Appetite and reward.
        Front Neuroendocrinol. 2010; 31: 85-103
      1. Koob GF, Volkow ND (2010): Neurocircuitry of addiction. Neuropsychopharmacology 35:217–238.

        • Berman R.M.
        • Narasimhan M.
        • Miller H.L.
        • Anand A.
        • Cappiello A.
        • Oren D.A.
        • et al.
        Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker?.
        Arch Gen Psychiatry. 1999; 56: 395-403
        • Hasler G.
        • Drevets W.C.
        • Manji H.K.
        • Charney D.S.
        Discovering endophenotypes for major depression.
        Neuropsychopharmacology. 2004; 29: 1765-1781
        • Hasler G.
        • Fromm S.
        • Carlson P.J.
        • Luckenbaugh D.A.
        • Waldeck T.
        • Geraci M.
        • et al.
        Neural response to catecholamine depletion in unmedicated subjects with major depressive disorder in remission and healthy subjects.
        Arch Gen Psychiatry. 2008; 65: 521-531
        • Nagatsu T.
        • Levitt M.
        • Udenfriend S.
        Tyrosine hydroxylase. The initial step in norepinephrine biosynthesis.
        J Biol Chem. 1964; 239: 2910-2917
        • Mignot E.
        • Laude D.
        Study of dopamine turnover by monitoring the decline of dopamine metabolites in rat CSF after alpha-methyl-p-tyrosine.
        J Neurochem. 1985; 45: 1527-1533
        • Stine S.M.
        • Krystal J.H.
        • Petrakis I.L.
        • Jatlow P.I.
        • Heninger G.R.
        • Kosten T.R.
        • et al.
        Effect of alpha-methyl-para-tyrosine on response to cocaine challenge.
        Biol Psychiatry. 1997; 42: 181-190
        • Verhoeff N.P.
        • Christensen B.K.
        • Hussey D.
        • Lee M.
        • Papatheodorou G.
        • Kopala L.
        • et al.
        Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: A replication study.
        Pharmacol Biochem Behav. 2003; 74: 425-432
        • Bremner J.D.
        • Vythilingam M.
        • Ng C.K.
        • Vermetten E.
        • Nazeer A.
        • Oren D.A.
        • et al.
        Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: Implications for the neural circuitry of depression.
        JAMA. 2003; 289: 3125-3134
        • Delgado P.L.
        • Miller H.L.
        • Salomon R.M.
        • Licinio J.
        • Heninger G.R.
        • Gelenberg A.J.
        • et al.
        Monoamines and the mechanism of antidepressant action: Effects of catecholamine depletion on mood of patients treated with antidepressants.
        Psychopharmacol Bull. 1993; 29: 389-396
        • Miller H.L.
        • Delgado P.L.
        • Salomon R.M.
        • Berman R.
        • Krystal J.H.
        • Heninger G.R.
        • et al.
        Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression.
        Arch Gen Psychiatry. 1996; 53: 117-128
        • Bruce K.R.
        • Steiger H.
        • Young S.N.
        • Kin N.M.
        • Israel M.
        • Levesque M.
        Impact of acute tryptophan depletion on mood and eating-related urges in bulimic and nonbulimic women.
        J Psychiatry Neurosci. 2009; 34: 376-382
        • Kaye W.H.
        • Gendall K.A.
        • Fernstrom M.H.
        • Fernstrom J.D.
        • McConaha C.W.
        • Weltzin T.E.
        Effects of acute tryptophan depletion on mood in bulimia nervosa.
        Biol Psychiatry. 2000; 47: 151-157
        • Smith K.A.
        • Fairburn C.G.
        • Cowen P.J.
        Symptomatic relapse in bulimia nervosa following acute tryptophan depletion.
        Arch Gen Psychiatry. 1999; 56: 171-176
        • Weltzin T.E.
        • Fernstrom M.H.
        • Fernstrom J.D.
        • Neuberger S.K.
        • Kaye W.H.
        Acute tryptophan depletion and increased food intake and irritability in bulimia nervosa.
        Am J Psychiatry. 1995; 152: 1668-1671
        • Miller H.L.
        • Delgado P.L.
        • Salomon R.M.
        • Heninger G.R.
        • Charney D.S.
        Effects of alpha-methyl-para-tyrosine (AMPT) in drug-free depressed patients.
        Neuropsychopharmacology. 1996; 14: 151-157
        • Kendler K.S.
        • Walters E.E.
        • Neale M.C.
        • Kessler R.C.
        • Heath A.C.
        • Eaves L.J.
        The structure of the genetic and environmental risk factors for six major psychiatric disorders in women. Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism.
        Arch Gen Psychiatry. 1995; 52: 374-383
        • First M.
        • Spitzer R.L.
        • Williams J.B.W.
        Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P).
        Biometrics Research, New York State Psychiatric Institute, New York2001
        • Grob S.
        • Pizzagalli D.A.
        • Dutra S.J.
        • Stern J.
        • Morgeli H.
        • Milos G.
        • et al.
        Dopamine-related deficit in reward learning after catecholamine depletion in unmedicated, remitted subjects with bulimia nervosa.
        Neuropsychopharmacology. 2012; 37: 1945-1952
        • Homan P.
        • Grob S.
        • Milos G.
        • Schnyder U.
        • Hasler G.
        Reduction in total plasma ghrelin levels following catecholamine depletion: relation to bulimic and depressive symptoms.
        Psychoneuroendocrinology. 2013; 38: 1545-1552
        • Hilbert A.
        • Tuschen-Caffier B.
        Eating Disorder Examination: Deutschsprachige Übersetzung.
        Verlag für Psychotherapie, Münster, Germany2006
        • Cooper Z.
        • Cooper P.J.
        • Fairburn C.G.
        The validity of the eating disorder examination and its subscales.
        Br J Psychiatry. 1989; 154: 807-812
        • Sysko R.
        • Walsh B.T.
        • Fairburn C.G.
        Eating Disorder Examination—Questionnaire as a measure of change in patients with bulimia nervosa.
        Int J Eat Disord. 2005; 37: 100-106
        • Hasler G.
        • Luckenbaugh D.A.
        • Snow J.
        • Meyers N.
        • Waldeck T.
        • Geraci M.
        • et al.
        Reward processing after catecholamine depletion in unmedicated, remitted subjects with major depressive disorder.
        Biol Psychiatry. 2009; 66: 201-205
        • Uher R.
        • Brammer M.J.
        • Murphy T.
        • Campbell I.C.
        • Ng V.W.
        • Williams S.C.
        • et al.
        Recovery and chronicity in anorexia nervosa: Brain activity associated with differential outcomes.
        Biol Psychiatry. 2003; 54: 934-942
        • Kaye W.H.
        • Gwirtsman H.E.
        • George D.T.
        • Jimerson D.C.
        • Ebert M.H.
        • Lake C.R.
        Disturbances of noradrenergic systems in normal weight bulimia: Relationship to diet and menses.
        Biol Psychiatry. 1990; 27: 4-21
        • Walsh B.T.
        • Wilson G.T.
        • Loeb K.L.
        • Devlin M.J.
        • Pike K.M.
        • Roose S.P.
        • et al.
        Medication and psychotherapy in the treatment of bulimia nervosa.
        Am J Psychiatry. 1997; 154: 523-531
        • Jimerson D.C.
        • Lesem M.D.
        • Kaye W.H.
        • Brewerton T.D.
        Low serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodes.
        Arch Gen Psychiatry. 1992; 49: 132-138
        • Kaye W.H.
        • Ballenger J.C.
        • Lydiard R.B.
        • Stuart G.W.
        • Laraia M.T.
        • O’Neil P.
        • et al.
        CSF monoamine levels in normal-weight bulimia: Evidence for abnormal noradrenergic activity.
        Am J Psychiatry. 1990; 147: 225-229
        • Lutter M.
        • Nestler E.J.
        Homeostatic and hedonic signals interact in the regulation of food intake.
        J Nutr. 2009; 139: 629-632
        • Broft A.
        • Shingleton R.
        • Kaufman J.
        • Liu F.
        • Kumar D.
        • Slifstein M.
        • et al.
        Striatal dopamine in bulimia nervosa: A PET imaging study.
        Int J Eat Disord. 2012; 45: 648-656
        • Frank G.K.
        • Oberndorfer T.A.
        • Simmons A.N.
        • Paulus M.P.
        • Fudge J.L.
        • Yang T.T.
        • et al.
        Sucrose activates human taste pathways differently from artificial sweetener.
        Neuroimage. 2008; 39: 1559-1569
        • McCann U.D.
        • Penetar D.M.
        • Belenky G.
        Acute dystonic reaction in normal humans caused by catecholamine depletion.
        Clin Neuropharmacol. 1990; 13: 565-568
        • Laruelle M.
        • D’Souza C.D.
        • Baldwin R.M.
        • Abi-Dargham A.
        • Kanes S.J.
        • Fingado C.L.
        • et al.
        Imaging D2 receptor occupancy by endogenous dopamine in humans.
        Neuropsychopharmacology. 1997; 17: 162-174
        • Brogden R.
        • Heel R.C.
        • Speight T.M.
        • Avery G.S.
        Alpha-methyl-p-tyrosine: A review of its pharmacological and clinical use.
        Drugs. 1981; 21: 81-89
        • Freeman M.E.
        • Kanyicska B.
        • Lerant A.
        • Nagy G.
        Prolactin: Structure, function, and regulation of secretion.
        Physiol Rev. 2000; 80: 1523-1631
        • Neumeister A.
        • Nugent A.C.
        • Waldeck T.
        • Geraci M.
        • Schwarz M.
        • Bonne O.
        • et al.
        Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls.
        Arch Gen Psychiatry. 2004; 61: 765-773